All In MedTech

Device Trial Radar · NCT07766187

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma (CODAH Trial)

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2032

Study completion Aug 2032

Sponsor

Lead sponsor
University of Wisconsin, MadisonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
HistoSonics, Inc.
First posted
Aug 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.

Conditions

  • Intrahepatic Cholangiocarcinoma

Interventions

  • HistotripsyDevice

    Histotripsy will be performed using the Edison® System (HistoSonics, Inc.), which is FDA cleared for destruction of liver tissue using non thermal focused ultrasound. Performed on Cycle 1 Day 8 (C1D8) to treat the Target Tumor.

  • DurvalumabDrug

    Durvalumab is an immunotherapy drug and will be administered on day 1 of each 28-day cycle as per local standards. Dosing of maintenance durvalumab is 1500mg IV per FDA labeling with administration performed over 60 minutes as per standard clinical practice.

  • BiopsyProcedure

    Two research biopsies are planned for cycle 1 day 3 and cycle 1 day 22, before and after histotripsy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Increase in Adaptive Immune System Response following histotripsyTime frame: data collected cycle 1 day 3 (C1D3) and cycle 1 day 22 (C1D22) (up to about 30 days with allowable procedural windows)
  2. Percent of Participants Experiencing Immune-mediated Adverse Events within 30 days of histotrispyTime frame: data collected up to day 38 (30 days post-histotripsy)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Wisconsin

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.